Status:
RECRUITING
Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?
Lead Sponsor:
Fundación para la Investigación del Hospital Clínico de Valencia
Conditions:
Adenocarcinoma of the Pancreas
Eligibility:
All Genders
18+ years
Brief Summary
Prospective multicenter study in which all patients with borderline or locally advanced pancreatic adenocarcioma undergoing neoadjuvant chemotherapy and surgical exploration with curative intent will ...
Detailed Description
Neoadjuvant chemotherapy followed by surgery represents the treatment of choice for patients with borderline and locally advanced pancreatic adenocarcinoma (PAC). Despite being the diagnostic techniqu...
Eligibility Criteria
Inclusion
- \- Patients with a diagnosis of borderline or locally advanced PAC of the head of the pancreas, as defined by the National Comprehensive Cancer Network (NCCN), who have received neoadjuvant treatment and who undergo surgical exploration with resective intent.
Exclusion
- Patients younger than 18 years of age.
- Patients under 18 years of age.
- Disease progression during neoadjuvant treatment.
- No preoperative CT scan.
- Refusal to participate in the study.
Key Trial Info
Start Date :
March 21 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06582342
Start Date
March 21 2024
End Date
December 30 2025
Last Update
August 6 2025
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital General de Alicante
Alicante, Spain
2
Hospital Universitario de Badajoz
Badajoz, Spain
3
Hospital del Mar (Barcelona)
Barcelona, Spain, 08003
4
Hospital Clínic de Barcelona
Barcelona, Spain